Does the media favor TRDA or TCRX?

In the previous week, Entrada Therapeutics had 3 more articles in the media than TScan Therapeutics. MarketBeat recorded 5 mentions for Entrada Therapeutics and 2 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 0.84 beat Entrada Therapeutics' score of 0.22 indicating that TScan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entrada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TScan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AKBA or TCRX?

In the previous week, Akebia Therapeutics and Akebia Therapeutics both had 2 articles in the media. TScan Therapeutics' average media sentiment score of 0.84 beat Akebia Therapeutics' score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TScan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

TScan Therapeutics (TCRX) Competitors

$0.99 +0.01 (+1.22%)

Closing price 04:00 PM Eastern

Extended Trading

$1.00 +0.01 (+0.51%)

As of 07:59 PM Eastern

Compare

TCRX vs. AVXL, TRDA, AKBA, ACIU, and FBRX

Should you buy TScan Therapeutics stock or one of its competitors? MarketBeat compares TScan Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TScan Therapeutics include Anavex Life Sciences (AVXL), Entrada Therapeutics (TRDA), Akebia Therapeutics (AKBA), AC Immune (ACIU), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical products" industry.

How does TScan Therapeutics compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Anavex Life Sciences has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. Anavex Life Sciences' return on equity of -38.76% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Anavex Life Sciences has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Anavex Life Sciences presently has a consensus price target of $21.33, indicating a potential upside of 714.25%. TScan Therapeutics has a consensus price target of $6.00, indicating a potential upside of 503.68%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Anavex Life Sciences is more favorable than TScan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Anavex Life Sciences has higher earnings, but lower revenue than TScan Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
TScan Therapeutics	$10.32M	6.29	-$129.77M	-$0.96	N/A

In the previous week, TScan Therapeutics had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 2 mentions for TScan Therapeutics and 0 mentions for Anavex Life Sciences. TScan Therapeutics' average media sentiment score of 0.84 beat Anavex Life Sciences' score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anavex Life Sciences	Neutral
TScan Therapeutics	Positive

Summary

Anavex Life Sciences beats TScan Therapeutics on 9 of the 14 factors compared between the two stocks.

How does TScan Therapeutics compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Entrada Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

TScan Therapeutics has lower revenue, but higher earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	9.56	-$143.75M	-$3.99	N/A
TScan Therapeutics	$10.32M	6.29	-$129.77M	-$0.96	N/A

In the previous week, Entrada Therapeutics had 3 more articles in the media than TScan Therapeutics. MarketBeat recorded 5 mentions for Entrada Therapeutics and 2 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 0.84 beat Entrada Therapeutics' score of 0.22 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TScan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TScan Therapeutics has a net margin of -1,360.61% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Entrada Therapeutics currently has a consensus target price of $17.50, suggesting a potential upside of 179.55%. TScan Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 503.68%. Given TScan Therapeutics' higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Entrada Therapeutics and TScan Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does TScan Therapeutics compare to Akebia Therapeutics?

Akebia Therapeutics (NASDAQ:AKBA) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Akebia Therapeutics has higher revenue and earnings than TScan Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.06	-$5.34M	-$0.08	N/A
TScan Therapeutics	$10.32M	6.29	-$129.77M	-$0.96	N/A

Akebia Therapeutics presently has a consensus target price of $4.67, indicating a potential upside of 398.79%. TScan Therapeutics has a consensus target price of $6.00, indicating a potential upside of 503.68%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TScan Therapeutics is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Akebia Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

In the previous week, Akebia Therapeutics and Akebia Therapeutics both had 2 articles in the media. TScan Therapeutics' average media sentiment score of 0.84 beat Akebia Therapeutics' score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TScan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 4.3% of Akebia Therapeutics shares are held by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Akebia Therapeutics has a net margin of -8.83% compared to TScan Therapeutics' net margin of -1,360.61%. Akebia Therapeutics' return on equity of -62.72% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-8.83%	-62.72%	-5.66%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

Summary

TScan Therapeutics beats Akebia Therapeutics on 8 of the 14 factors compared between the two stocks.

How does TScan Therapeutics compare to AC Immune?

AC Immune (NASDAQ:ACIU) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

In the previous week, TScan Therapeutics had 2 more articles in the media than AC Immune. MarketBeat recorded 2 mentions for TScan Therapeutics and 0 mentions for AC Immune. AC Immune's average media sentiment score of 1.00 beat TScan Therapeutics' score of 0.84 indicating that AC Immune is being referred to more favorably in the media.

Company	Overall Sentiment
AC Immune	Positive
TScan Therapeutics	Positive

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 6.3% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

TScan Therapeutics has a net margin of -1,360.61% compared to AC Immune's net margin of -1,788.02%. TScan Therapeutics' return on equity of -91.94% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

AC Immune has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

AC Immune presently has a consensus price target of $7.50, indicating a potential upside of 242.47%. TScan Therapeutics has a consensus price target of $6.00, indicating a potential upside of 503.68%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

AC Immune has higher earnings, but lower revenue than TScan Therapeutics. AC Immune is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	51.71	-$85.03M	-$0.82	N/A
TScan Therapeutics	$10.32M	6.29	-$129.77M	-$0.96	N/A

Summary

TScan Therapeutics beats AC Immune on 10 of the 16 factors compared between the two stocks.

How does TScan Therapeutics compare to Forte Biosciences?

TScan Therapeutics (NASDAQ:TCRX) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

TScan Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 503.68%. Forte Biosciences has a consensus target price of $67.00, indicating a potential upside of 327.57%. Given TScan Therapeutics' higher possible upside, equities analysts clearly believe TScan Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, TScan Therapeutics had 2 more articles in the media than Forte Biosciences. MarketBeat recorded 2 mentions for TScan Therapeutics and 0 mentions for Forte Biosciences. TScan Therapeutics' average media sentiment score of 0.84 beat Forte Biosciences' score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Positive
Forte Biosciences	Neutral

TScan Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.87, suggesting that its stock price is 187% more volatile than the broader market.

Forte Biosciences has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. TScan Therapeutics' return on equity of -91.94% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Forte Biosciences	N/A	-106.17%	-85.50%

Forte Biosciences has lower revenue, but higher earnings than TScan Therapeutics. Forte Biosciences is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	6.29	-$129.77M	-$0.96	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

TScan Therapeutics beats Forte Biosciences on 10 of the 14 factors compared between the two stocks.

Get TScan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TCRX vs. The Competition

Export

Metric	TScan Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$64.17M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-1.04	18.61	23.92	23.74
Price / Sales	6.29	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	0.46	8.04	10.28	6.78
Net Income	-$129.77M	$23.89M	$3.57B	$337.51M
7 Day Performance	-1.59%	-5.97%	-1.43%	-2.72%
1 Month Performance	-21.12%	2.78%	3.27%	1.87%
1 Year Performance	-44.78%	36.26%	23.37%	26.60%

TScan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TCRX TScan Therapeutics	3.1378 of 5 stars	$0.99 +1.2%	$6.00 +503.7%	-45.5%	$64.17M	$10.32M	N/A	100
AVXL Anavex Life Sciences	1.4991 of 5 stars	$2.71 -10.7%	$21.33 +688.7%	-68.9%	$280.80M	N/A	N/A	40	Upcoming Earnings
TRDA Entrada Therapeutics	3.9004 of 5 stars	$6.55 -7.4%	$18.25 +178.6%	-23.4%	$274.46M	$25.42M	N/A	110	Analyst Forecast
AKBA Akebia Therapeutics	1.6738 of 5 stars	$0.94 -7.9%	$4.67 +397.0%	-76.4%	$273.62M	$236.20M	N/A	430
ACIU AC Immune	2.8572 of 5 stars	$2.41 -9.6%	$7.50 +211.9%	+10.3%	$270.72M	$3.70M	N/A	140	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TCRX) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TScan Therapeutics (TCRX) Competitors

TCRX vs. AVXL, TRDA, AKBA, ACIU, and FBRX

How does TScan Therapeutics compare to Anavex Life Sciences?

Summary

How does TScan Therapeutics compare to Entrada Therapeutics?

Summary

How does TScan Therapeutics compare to Akebia Therapeutics?

Summary

How does TScan Therapeutics compare to AC Immune?

Summary

How does TScan Therapeutics compare to Forte Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TScan Therapeutics (TCRX) Competitors

TCRX vs. AVXL, TRDA, AKBA, ACIU, and FBRX

How does TScan Therapeutics compare to Anavex Life Sciences?

Is AVXL or TCRX more profitable?

Which has more risk and volatility, AVXL or TCRX?

Do institutionals and insiders have more ownership in AVXL or TCRX?

Do analysts prefer AVXL or TCRX?

Which has stronger valuation & earnings, AVXL or TCRX?

Does the media favor AVXL or TCRX?

Summary

How does TScan Therapeutics compare to Entrada Therapeutics?

Do insiders and institutionals hold more shares of TRDA or TCRX?

Which has more volatility & risk, TRDA or TCRX?

Which has stronger valuation & earnings, TRDA or TCRX?

Does the media favor TRDA or TCRX?

Is TRDA or TCRX more profitable?

Do analysts rate TRDA or TCRX?

Summary

How does TScan Therapeutics compare to Akebia Therapeutics?

Which has higher earnings & valuation, AKBA or TCRX?

Do analysts recommend AKBA or TCRX?

Which has more volatility and risk, AKBA or TCRX?

Does the media favor AKBA or TCRX?

Do insiders & institutionals have more ownership in AKBA or TCRX?

Is AKBA or TCRX more profitable?

Summary

How does TScan Therapeutics compare to AC Immune?

Does the media prefer ACIU or TCRX?

Do insiders and institutionals believe in ACIU or TCRX?

Is ACIU or TCRX more profitable?

Which has more risk and volatility, ACIU or TCRX?

Do analysts prefer ACIU or TCRX?

Which has higher valuation and earnings, ACIU or TCRX?

Summary

How does TScan Therapeutics compare to Forte Biosciences?

Do analysts prefer TCRX or FBRX?

Does the media refer more to TCRX or FBRX?

Which has more volatility and risk, TCRX or FBRX?

Is TCRX or FBRX more profitable?

Which has better valuation & earnings, TCRX or FBRX?

Do institutionals & insiders have more ownership in TCRX or FBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX vs. The Competition

TScan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools